Arbutus Biopharma (ABUS) has released an update.
Arbutus Biopharma Corporation announced the retirement of its co-founder and Chief Scientific Officer, Dr. Michael J. Sofia, effective December 31, 2024. Dr. Sofia, a renowned scientist in antiviral drug development, has made significant contributions to the company, particularly in the pursuit of a functional cure for chronic hepatitis B virus (HBV). The company remains committed to advancing the clinical development of HBV therapeutics initiated under Dr. Sofia’s leadership.
For further insights into ABUS stock, check out TipRanks’ Stock Analysis page.
